Q-omics provides the consensus-scored NUBPL profile across patient tissues and cancer cell-line models. NUBPL expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NUBPL is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NUBPL RNA expression shows 20,477 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where NUBPL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUBPL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUBPL survival associations across molecular data types. NUBPL RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUBPL RNA expression–survival associations across cancer types. High NUBPL expression shows unfavorable associations in BLCA, HNSC and UVM, but favorable associations in KIRC, BRCA and READ. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NUBPL RNA expression.
This table summarizes NUBPL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NUBPL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUBPL shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in LUAD, HNSC and CHOL. The KIRC box plot shows higher NUBPL RNA expression in normal versus tumor tissue (log2 FC = −0.676, t-test p < 0.001).
This table shows molecular features associated with NUBPL in patient tissues and cancer cell lines. In patient samples, NUBPL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NUBPL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
